Instead, gain-of-function mutations of IDH1 and IDH2 isoforms lead to the production and accumulation of L- and D-2-hydroxyglutarate (L-/D-2HG) in acute myeloid leukemia, glioma, chondrosarcoma, and cholangiocarcinoma. Here, IDH2 is linked to central nervous system cancer.